Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:37:16 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CDTX - CIDARA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CDTX - Q0.112.52·13.000.112.63-0.37-2.8199.62,4351,86012.65  13.43  11.5729.60  10.00419:58:5608:0015 min RT 2¢

Recent Trades - Last 10 of 1860
Time ETExPriceChangeVolume
19:58:56Q12.53-0.478
19:35:09Q12.70-0.30150
18:29:22Q12.52-0.4850
18:28:40Q13.00 3
18:24:24Q12.52-0.4810
17:22:45Q12.52-0.485
17:01:35Q12.52-0.482
16:35:55Q12.52-0.4825
16:35:55Q12.30-0.7010
16:18:57Q12.70-0.3043

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-26 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
2024-04-24 16:05U:CDTXNews ReleaseCidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
2024-04-24 16:01U:CDTXNews ReleaseCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
2024-04-22 17:11U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-04-22 17:06U:CDTXNews ReleaseCidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
2024-04-22 08:50U:CDTXNews ReleaseCidara Therapeutics Announces Reverse Stock Split
2024-04-05 15:00U:CDTXNews ReleaseCidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-06 08:00U:CDTXNews ReleaseCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
2024-02-12 08:00U:CDTXNews ReleaseCidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
2024-01-29 16:30U:CDTXNews ReleaseCidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
2023-12-22 07:30U:CDTXNews ReleaseCidara Therapeutics Announces European Approval of REZZAYO ‚ ® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
2023-12-07 08:00U:CDTXNews ReleaseCidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-12-06 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
2023-11-30 08:00U:CDTXNews ReleaseCidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-11-20 08:00U:CDTXNews ReleaseCidara Therapeutics Named as a San Diego Metro Area Top Workplace
2023-11-03 12:00U:CDTXNews ReleaseCidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC ¢ € ™s 38 ¡ µ — Š ° Annual Meeting
2023-11-02 16:15U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-10-13 10:34U:CDTXNews ReleaseCidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
2023-10-11 08:30U:CDTXNews ReleaseCidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
2023-09-29 16:52U:CDTXNews ReleaseCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)